Human curation is more important than ever in an age of ‘Infobesity’ as it offers qualities that are not replicable by AI. We show how a fusion of AI synthesis and strategic human curation can help to drive business impact.
In today’s fast-moving, shape-shifting world, it seems virtually every business, every marketer, and every researcher wants to be agile. But, what exactly does agility mean?
Artificial Intelligence is often mooted as the ‘future’ for our industry. Many lead us to believe that we are headed for an AI utopia; that ‘optimised’ ad experiences fuelled by big data insights gleaned solely by machines, tailored to individuals, and served to them programatically with impeccable timing in the right time and right context, is almost within reach. However, when we take a step back to consider this, how close are we really; and is it even what we want at all?
Despite the advent of targeted therapies and the associated rise in the use of companion and complementary diagnostics, we are only just emerging from the initial exploratory stages of oncology biomarker testing. As will be argued in this paper, we are on the cusp of a much more radical revolution, and the molecular diagnostics landscape is set to change dramatically in the coming decades. It is crucial that any company entering this space prepare for this imminent upheaval and plan their launch strategy accordingly.
The genesis of a new realm of possibility in manufacturing and supply chain. 3D printing is truly revolutionary. The ability to print bespoke parts and products will transform industrial manufacturing as well as many other sectors including Healthcare.
Advances in science and data let us better support clients in a world that is constantly changing. The Ipsos Science Centre is a world class Data Science team at the intersection of statistics and computer science that allows us to leverage existing and new information in innovative ways to improve the insights and actions of decision makers.
